壁报讨论会

Welcome! Thanks for stopping by my poster. I'm Dr. Lee, and this research focuses on novel targeted therapies for glioblastoma.

Hello, Dr. Lee. I'm Dr. Chen. Your work looks fascinating. Could you walk me through your primary findings, especially concerning the patient response rates?

Certainly, Dr. Chen. As you can see here, we observed a statistically significant improvement in progression-free survival in the treatment arm. Specifically, our patient response rates were around 35%, which is quite promising compared to current standard-of-care treatments.

That's impressive. Did you encounter any unexpected adverse events, or were the side effect profiles largely in line with what was anticipated for this class of drugs?

Good question. We did note a higher incidence of dermatological toxicities, specifically a rash, in a small subset of patients. However, these were generally manageable with topical treatments and didn't lead to treatment discontinuation.

Fascinating. Your methodology for assessing tumor response, particularly the imaging protocols, seems quite thorough. What led you to choose this specific combination of imaging modalities?

We opted for a multi-modal approach combining standard MRI with advanced perfusion imaging to gain a more comprehensive understanding of tumor vascularity and metabolic activity. This allowed us to detect subtle changes that might be missed with conventional imaging alone.

That makes perfect sense. This is really cutting-edge work, Dr. Lee. Thank you for taking the time to explain it so thoroughly. I'd love to follow up on this research as it progresses.

My pleasure, Dr. Chen. I appreciate your insightful questions. Feel free to grab one of my cards if you'd like to reach out. We're indeed very excited about the next phases of this trial.